Kornimate/medical-research-clean huggingface dataset:
prevalence and associated factors of post-operative nausea and vomiting

Conditions: Postoperative Nausea and Vomiting

Summary: postoperative nausea and vomiting (ponv) is a surgical complication defined as any nausea, and vomiting with in the first 24-48 hours after surgery in inpatients. nausea is an unpleasant feeling or desire to vomit without expulsive muscular movement, while vomiting is a forceful expulsion or reflux of the gastric contents through the mouth. postoperative nausea and vomiting is one of the most common complication associated anesthesia and surgery. it is considered the most common cause of morbidity, and it has significant effects on patient satisfaction. in spite of recent development of anesthesia and surgical techniques, the incidence of ponv remains high. this common anesthetic and surgical side effect has been reported to increase patient dissatisfaction and can be just as distressing to patients as postoperative pain is.

postoperative nausea and vomiting is caused by multiple factors; patient related, anesthesia and surgery related risk factors have been identified. patient related factors include female gender post-puberty, nonsmoking status, history of ponv or motion sickness, and childhood after infancy and younger adulthood. use of volatile anesthetics, nitrous oxide, large-dose neostigmine, or intraoperative or postoperative opioids are factors related to anesthesia, while the type of procedures like gynecologic, ophthalmological, ontological, thyroid surgery laparoscopic, abdominal surgery and duration of the procedure are some of surgery related risk factors. the incidence of ponv for over multiple individual studies conducted around the world, has been estimated to be 25% to 30% and up to 80% in high risk groups. the incidence of ponv is estimated to range from 20%-36%. post-operative nausea and vomiting imposes multiple impacts on patients. the main one being a decrease satisfaction, but more importantly it leads to dehydration, electrolyte imbalance, aspiration of gastric secretions, esophageal rupture, bleeding, increased morbidity, and delayed discharge from hospital. the study aimed to assess the incidence and associated factors of post-operative nausea and vomiting, which is believed to be a main contributing factor to dissatisfaction and delayed recovery seen in our country. the study was done from february to april 2022 in patients undergoing elective surgery at dessie comprehensive specialized hospital, ethiopia.

Eligibility criteria:
inclusion criteria: * all adult patients, who underwent elective surgery under anesthesia in the study period. exclusion criteria: * patients who didn't gain their consciousness postoperatively, patients who underwent emergency surgery, patients who were re-operated on during the study period, surgical patients medical illness that predispose them to nausea and vomiting, and patients discharged before 24 hours postoperatively
effect of acetazolamide on maximal exercise performance in lowlanders older than 40 years at altitude

Conditions: Altitude Hypoxia

Summary: randomized, placebo controlled trial evaluating the effect of acetazolamide on maximal exercise performance in lowlanders older than 40 years travelling from 760 m to 3'100 m.

this is a randomized, placebo-controlled, double-blind parallel trial evaluating the effect of acetazolamide intake on the maximal exercise performance in lowlanders older than 40 years travelling to altitude. participants living in the bishkek area, kyrgyzstan (760m), will be transferred by car within 4h to the tuja ashu high altitude clinic (3'100 m), and stay there for 2 days. acetazolamide 375mg/day (or placebo), will be administered before departure at 760 m and during the stay at altitude. outcomes will be assessed during the stay at 3'100 m. an interim analysis will be carried out when 80 participants will have completed the study or after the first year. the peto's method will be used and the trial will be stopped when pre-specified futility boundaries were crossed.

Eligibility criteria:
inclusion criteria: * healthy men and women, age 40-75 yrs, without any disease and need of medication. * born, raised and currently living at low altitude (\<800m). * written informed consent. * kyrgyz ethnicity exclusion criteria: * any active respiratory, cardiovascular or other disease requiring regular treatment or being otherwise relevant for tolerance of hypoxia or altitude exposure. * any condition that may interfere with protocol compliance including current heavy smoking (\>20 cigarettes per day or \>20 pack-years with active smoking during the last 10 years), regular use of alcohol. * allergy to acetazolamide and other sulfonamides.

Keywords: healthy participants older than 40 years exercise performance prevention acetazolamide
ak112 and cadonilimab combined with chemotherapy for 1l treatment of metastatic pancreatic cancer

Conditions: Metastatic Pancreatic Ductal Adenocarcinoma

Summary: this trial is a phase ib/ii study. all patients are stage iv pancreatic cancer (pdac) patients with eastern cooperative oncology group (ecog) performance status of 0-1. the purpose of this study is to evaluate the safety and efficacy of ak112 and cadonilimab combined with chemotherapy as first-line treatment for patients with metastatic pancreatic cancer.


Eligibility criteria:
inclusion criteria: 1. be able and willing to provide written informed consent and to comply with all requirements of study participation (including all study procedures). 2. ≥18 years old and ≤ 75 years (regardless of sex). 3. ecog performance status 0-1 4. life expectancy longer than 3 months. 5. histologically or cytologically confirmed diagnosis of metastatic pancreatic ductal carcinoma (pdac). 6. no prior systemic anti-tumor therapy for metastatic pdac. 7. adequate organ function. 8. measurable disease based on response evaluation criteria in solid tumors (recist) 1.1. exclusion criteria: 1. histological or cytological diagnosis of other pathological types. 2. brca1/2 or palb2 mutations. 3. participating in another clinical research. 4. active central nervous system (cns) metastases. 5. undergoing systemic antiangiogenic therapy. 6. acute or subacute pancreatitis. 7. other known malignancies within five years. 8. active infection requiring systemic therapy.
clinical estimation of dental anxiety

Conditions: Dental Anxiety

Summary: introduction: dental anxiety (da) is treatable and preventable when dental personnel correctly estimate the patient's level of da. objective: to evaluate dental personnel's ability to estimate da.

method: all public dental clinics in the region of östergötland, sweden, were asked to consecutively recruit adult patients returning for their annual examination. the patient rated da using the modified dental anxiety scale (mdas) and a visual analogue scale of dental anxiety (da-vas). the patient also recorded gender, age, level of education and confidence in handling da. after the examination, the dental personnel estimated the patient's level of da (eda) on a vas. the examiner also recorded gender, age, profession, years of experience, country of education, interest in da, special education concerning da and confidence in ability to handle da.

Eligibility criteria:
inclusion criteria: adult patients returning for their annual examination on a public dental clinics in the region of östergötland, sweden during a two week period. exclusion criteria: inability to fill in the questionnaire
use of mucolytic solution before upper endoscopy

Conditions: Gastric Cancer; Gastroscopy

Summary: the study was designed to evaluate the effectiveness of the maximum dose of mucolytic solution used before upper endoscopy on the visibility of the gastric mucosa

residual gastric content containing mucus, bubbles, bile and food particles may limit visibility of gastric mucosa and therefore diagnostic yield of upper endoscopy, especially in cases of early neoplastic lesions. data on benefit of peroral mucolytic solution administered before upper endoscopy are limited.

Eligibility criteria:
inclusion criteria: * age \> 18 years, signed informed consent, diagnostic gastroscopy exclusion criteria: * age \< 18 years, interventional gastroscopy, known disease of the upper gi tract and/or history of surgery of gi tract, gastroscopy indicated of bleeding, dysphagia or ileus, liver cirrhosis, general anesthesia, allergy to mucolytic solution components, pregnancy
biofeedback with heart sound following trauma

Conditions: Young Earthquake Survivors

Summary: the project aims to assess the long-term risk of trauma-induced stress in young persons. using non-invasive sound therapy to assess the effects on the vagal nerve via cardiovascular effects and neural activity will provide biofeedback in these individuals.

background: some countries have suffered and will continue to suffer great destruction as a result of wars, epidemics, earthquakes, and other natural catastrophes. when individuals are exposed to specific psychological or physical traumas, they can develop stress-related disorders. this can lead to irreversible changes in the autonomic nervous system and cardiovascular disorders. when subjected to a new stress test, traumatized/previously exposed participants may show more pronounced behavioral changes, intolerance, and greater fatigue responses as compared to pre-trauma. to reduce trauma-associated responses from recurring again in the future, especially in young people, it is necessary to take preventive measures. alternative solutions must be designed for counseling, medication, phytotherapy, etc. this study aims to examine how individuals cope with trauma-related situations using a biofeedback method, which could be developed to manage stress-related coping. the emotional and psychological states of earthquake victims will be assessed using a protocol based on biomedical (neuro-cardiac) signals and the sound of the person's own heart. this sound will be applied at a fixed frequency or in real-time with allostatic auditory stimulation. a resonance stabilizing the autonomic nervous system will thus provide biofeedback to the participants. methods: to examine the different states, biological signals will be measured and recorded, such as electrocardiography (ecg), phonocardiography (pcg), electrodermal activity, respiratory rhythm, and near-infrared spectroscopic imaging (fnirs). deep learning models will optimally process the collected data and evaluate the results. impact: the project aims to assess the long-term risk of trauma-induced stress in young persons. using non-invasive sound therapy to assess the effects on the vagal nerve via cardiovascular effects and neural activity will provide biofeedback in these individuals.

Eligibility criteria:
inclusion criteria: * 30 earthquake survivor university students between 20 and 25 will participate in the experiment. participants will be healthy, non-obese men (n=15) and women (n=15). in particular, all participants should have experienced the earthquake disaster in the local region. all participants must be free of any chronic or acute infection, neurological, psychiatric, and/or cardiovascular disease. exclusion criteria: * they must be non-smokers, have no alcohol or drug addiction, and not be under any medical treatment. pregnant or breastfeeding women will not be included in the study.

Keywords: biofeedback, trauma, allostasis
a study of bbi503 in adult patients with advanced solid tumors

Conditions: Cancer, Advanced Solid Tumors

Summary: this is an open label, single arm dose escalation study of bbi503 in adult patients with advanced solid tumors.


Eligibility criteria:
inclusion criteria: 1. signed written informed consent must be obtained and documented according to international conference on harmonization (ich)- good clinical practice (gcp), the local regulatory requirements, and permission to use private health information in accordance with the health insurance portability and accountability act (hippa) prior to study-specific screening procedures 2. a histologically or cytologically confirmed solid tumor that is metastatic, unresectable, or recurrent and for which standard curative or palliative therapies do not exist or are no longer effective. 3. ≥ 18 years of age 4. measurable disease as defined by response evaluation criteria in solid tumors (recist) 5. karnofsky performance status ≥ 70% 6. male or female patients of child-producing potential must agree to use contraception or avoidance of pregnancy measures during the study and for 30 days after the last bbi503 dose 7. females of childbearing potential must have a negative serum pregnancy test 8. aspartate transaminase (ast) and alanine transaminase (alt) \< or equal to 1.5 × upper limit of normal (uln) 9. hemoglobin (hgb) ≥ 10 g/dl 10. total bilirubin \< or equal to 1.5 × uln 11. creatinine \ 60 ml/min/1.73 m\^2 for patients with creatinine levels above institutional normal 12. absolute neutrophil count \< or equal to 1.5 x 10\^9/l 13. platelets ≥ 100 x 10\^9/l 14. life expectancy ≥ 3 months exclusion criteria: 1. anti-cancer chemotherapy, radiotherapy, immunotherapy, or investigational agents within four weeks of first dose with the exception for a single dose radiation up to 8 gray (equal to 800 rad) with palliative intent for pain control up to 14 days before beginning the administration of bbi503 2. surgery within 4 weeks prior to first dose 3. any known untreated brain metastases. treated subjects must be stable for 4 weeks after completion of that treatment, with image documentation required. patients must have no clinical symptoms from brain metastases and must be either off steroids or on a stable dose of steroids for at least 2 weeks prior to protocol enrollment. patients with known leptomeningeal metastases are excluded, even if treated. 4. pregnant or breastfeeding 5. significant gastrointestinal disorder(s), in the opinion of the principal investigator, (e.g., crohn's disease, ulcerative colitis, extensive gastric resection and small intestinal resection) 6. unable or unwilling to swallow bbi503 capsules daily 7. uncontrolled intercurrent illness including, but not limited to ongoing or active infection, clinically significant non-healing or healing wounds, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, significant pulmonary disease (shortness of breath at rest or mild exertion), uncontrolled infection or psychiatric illness/social situations that would limit compliance with study requirements
comparison of techniques in repair of unilateral cleft lip

Conditions: Unilateral Cleft Lip

Summary: over the past century, there have been major advances in unilateral cleft-lip repair techniques toward the method's modern form. the first documented cleft-lip repair involved simple freshening and approximation of the cut cleft edges, followed by the use of curved incisions to allow lengthening of the lip. straight-line closure repairs were used in the early 1900; however, straight-line closures had the disadvantage of creating a vertical scar contracture, leading to notching of the lip. this led to the development of several methods in the mid-twentieth century that are grouped as quadrangular flaps, triangular flaps, and rotation-advancement techniques. the two basic techniques that are most commonly used for unilateral cleft lip (ucl) closure are the tennison-randall and the millard rotation_advancement techniques. both techniques address the importance of repositioning the lip muscle (orbicularis oris) in the correct anatomic orientation for optimal aesthetic and functional outcomes. the ultimate goal of cleft lip surgery is to achieve a perfectly symmetrical lip and nose. it has been shown that for the general population, the more symmetrical the face, the more attractive the face is. the appearance and symmetry of the nasolabial region is also seen as one of the most important characteristics when evaluating the results of any facial surgery. measurement of treatment outcome is vital to evaluate the success of cleft management and the degree of improvement, especially in the present age of evidence-based medicine where treatment guidelines for best practice are becoming an integral part of contemporary clinical practice. the good goal of cleft lip repair is a symmetrical and balanced lip with minimal scar restoring the natural contours of the face, as well as correcting functional anatomy. objectives to evaluate the quantitative (anthropometric) assessment of modified millard technique in comparison to tennison_ randall technique in unilateral cleft lip (ucl) repair.


Eligibility criteria:
inclusion criteria: 1. patient with age from 2 months old to 6 months old. 2. patient with unilateral cleft lip complete or incomplete type. exclusion criteria: 1. patient with age less than 2 months old or more than 6 months old. 2. patients with bilateral cleft lip 3. patients with recurrent cleft lip. 4. patients with associated major congenital anomalies like major cardiac anomalies.
effect of rosuvastatin on triglyceride levels in mexican hypertriglyceridemic patients

Conditions: Hypertriglyceridemia; Hyperlipoproteinemia Type IV; Hyperlipoproteinemia Type V; Hyperlipoproteinemia Type IIb; Hyperlipidemia

Summary: the primary purpose of this trial is to determine if the treatment with rosuvastatin 10 and 20mg/day during 8 weeks in hypertriglyceridemic patients will reduce their triglyceride levels.


Eligibility criteria:
inclusion criteria: * patients older than 18 years, both genders, without any previous treatment with statins or other lipid lowering drugs for at least 6 months * with elevated triglycerides above 200 and below 800mg/dl and willing to follow all study procedures including assisting to clinics, fasting before blood samples and signing a written consent exclusion criteria: * high levels of low-density lipoprotein cholesterol (ldl-c) * unstable cardiovascular condition or awaiting a myocardial revascularization * congestive cardiac failure * uncontrolled diabetes * cancer * uncontrolled hypothyroidism * familial hypercholesterolemia * liver/muscle disease * pregnancy * other

Keywords: triglycerides hypertriglyceridemia statins rosuvastatin hyperlipoproteinemia fredrickson type iib or iv
satraplatin for patients with metastatic breast cancer (mbc)

Conditions: Metastatic Breast Cancer

Summary: to determine the objective response rate (orr) of oral satraplatin in patients with metastatic breast cancer.

this is a phase ii open label, nonrandomized study for patients with metastatic breast cancer. what is satraplatin: satraplatin is a member of the platinum-based class of chemotherapy drugs. platinum-based drugs have been clinically proven to be one of the most effective classes of anticancer therapies. unlike the currently marketed platinum-based drugs, satraplatin can be given orally.

Eligibility criteria:
1. has cytologically or pathologically confirmed breast cancer that is metastatic 2. must have had prior herceptinò therapy if patient has her2+ (overexpressing) breast cancer. her2 is considered overexpressed if it is 3+ by ihc or if the gene is amplified by flourescence in situ hybridization (fish) 3. has had no more than 1 prior chemotherapy regimen for mbc 4. has had no prior platinum-based therapy 5. has an ecog performance status (ps) 0-2
gabra2 and the pharmacokinetics of risk for alcoholism (gpra)

Conditions: Alcoholism

Summary: this study will assess whether the presence of a particular form of a gene, gabra2, affects the functional responses of the human brain to alcohol administration and will evaluate that relationship in the context of factors known to increase the risk for future alcoholism.

each subject completed a total of 2 2.8 hr-long clamping sessions.within each session, procedures differed only by the content of the infusate. in one session, 6% ethanol was infused. in the other session, only vehicle was infused, quantifying the placebo response for every subject. the order of alcohol or placebo sessions was counterbalanced; subjects were blind to which session was which; sessions were scheduled to occur approximately 2 weeks apart. measures were collected before, and at beginning and end of infusion, and included subjective perceptions, emg, eeg, stop-signal performance, eye movements, and auditory responses. design allowed analysis of effect of alcohol vs placebo, initial effect of alcohol and acute tolerance to alcohol.

Eligibility criteria:
inclusion criteria: * european american male and females between 21-27 years of age. * good health as determined by medical history, physical exam, and laboratory tests. * females must have a negative urine pregnancy (hcg) test at the start of each study session. * people who consume 0.10 standard drinks per week (12 g-ethanol) per liter of total body water when averaged over the preceding month, or more, or who have consumed more than 0.10 standard drinks per liter of total body water on any one occasion in the last month. exclusion criteria: * inability to read or comprehend eighth grade english. * inability to hear or comprehend verbal instructions, or inability or unwillingness to cooperate with the procedures required for the study. * inability to resolve 2 dots, each 2 mm in diameter with centers placed 5 mm apart on a card placed 20 inches from the bridge of the nose, or the need to wear eyeglasses to do so. * current or prior history of any serious disease, including head trauma causing loss of consciousness, cancer, cns, cardiovascular, respiratory, gastrointestinal, hepatic, renal, endocrine, or alcohol or drug dependence, but not alcohol abuse or nicotine dependence. * positive hepatitis or hiv test at screening, provided subject consented to these tests. * current or prior history of alcohol-induced flushing reactions. * current diagnosis of axis-i psychiatric illness. * positive result on urine drug screen obtained at the face-to-face interview. * pregnancy, as determined by urine hcg on each day of laboratory testing, or intention to become pregnant for women. * use of medications known to interact with alcohol within 2 weeks of the study.